References: 1. Waldman SA, Camilleri M. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut. 2018;67(8):1543-1552. 2. Trulance (plecanatide) [package insert]. Bridgewater, NJ: Salix Pharmaceuticals, Inc.; 2019. 3. Patwa V, Joshi A, Thadi A, et al. Plecanatide, like uroguanylin, activates guanylate cyclase-C signaling in a pH-dependent manner in T84 cells, and in murine intestinal epithelial cells and tissues. Presented at: Digestive Disease Week; May 21-24, 2016; San Diego, CA. 4. Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58(9):2580-2586. 5. Liu D, Overbey D, Watkinson LD, et al. In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone. Anticancer Res. 2009;29(10):3777-3783. 6. DeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2017;10(11):837-851. 7. Miner PB Jr, Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112(4):613-621. 8. Hannig G, Tchemychev B, Kurtz CB, et al. Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain. Front Mol Neurosci. 2014;7:31.